Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
Status:
Completed
Trial end date:
2017-04-18
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of the addition of ertugliflozin
(MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who
have inadequate glycemic control on metformin. The primary hypothesis of this study is that
after 52 weeks, the change from baseline in hemoglobin A1c (A1C) in participants treated with
the addition of ertugliflozin 15 mg once daily is non-inferior compared with that in
participants treated with the addition of glimepiride.